<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:43:43Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9607737" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9607737</identifier>
        <datestamp>2022-10-28</datestamp>
        <setSpec>npgopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Nature</journal-id>
              <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
              <journal-title-group>
                <journal-title>Nature</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-0836</issn>
              <issn pub-type="epub">1476-4687</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9607737</article-id>
              <article-id pub-id-type="pmcid">PMC9607737</article-id>
              <article-id pub-id-type="pmc-uid">9607737</article-id>
              <article-id pub-id-type="pmid">36289334</article-id>
              <article-id pub-id-type="pmid">36289334</article-id>
              <article-id pub-id-type="publisher-id">5368</article-id>
              <article-id pub-id-type="doi">10.1038/s41586-022-05368-8</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Neoadjuvant relatlimab and nivolumab in resectable melanoma</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6876-278X</contrib-id>
                  <name>
                    <surname>Amaria</surname>
                    <given-names>Rodabe N.</given-names>
                  </name>
                  <address>
                    <email>rnamaria@mdanderson.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Postow</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Burton</surname>
                    <given-names>Elizabeth M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tetzlaff</surname>
                    <given-names>Michael T.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7787-0421</contrib-id>
                  <name>
                    <surname>Ross</surname>
                    <given-names>Merrick I.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7422-0661</contrib-id>
                  <name>
                    <surname>Torres-Cabala</surname>
                    <given-names>Carlos</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4530-7765</contrib-id>
                  <name>
                    <surname>Glitza</surname>
                    <given-names>Isabella C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Duan</surname>
                    <given-names>Fei</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Milton</surname>
                    <given-names>Denái R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0888-9601</contrib-id>
                  <name>
                    <surname>Busam</surname>
                    <given-names>Klaus</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Simpson</surname>
                    <given-names>Lauren</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2393-2172</contrib-id>
                  <name>
                    <surname>McQuade</surname>
                    <given-names>Jennifer L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wong</surname>
                    <given-names>Michael K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gershenwald</surname>
                    <given-names>Jeffrey E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6010-5590</contrib-id>
                  <name>
                    <surname>Lee</surname>
                    <given-names>Jeffrey E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goepfert</surname>
                    <given-names>Ryan P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keung</surname>
                    <given-names>Emily Z.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fisher</surname>
                    <given-names>Sarah B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6422-2997</contrib-id>
                  <name>
                    <surname>Betof-Warner</surname>
                    <given-names>Allison</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8065-4412</contrib-id>
                  <name>
                    <surname>Shoushtari</surname>
                    <given-names>Alexander N.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9087-0012</contrib-id>
                  <name>
                    <surname>Callahan</surname>
                    <given-names>Margaret</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coit</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bartlett</surname>
                    <given-names>Edmund K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bello</surname>
                    <given-names>Danielle</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Momtaz</surname>
                    <given-names>Parisa</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8596-0200</contrib-id>
                  <name>
                    <surname>Nicholas</surname>
                    <given-names>Courtney</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gu</surname>
                    <given-names>Aidi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Xuejun</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Korivi</surname>
                    <given-names>Brinda Rao</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8135-8001</contrib-id>
                  <name>
                    <surname>Patnana</surname>
                    <given-names>Madhavi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1339-1517</contrib-id>
                  <name>
                    <surname>Patel</surname>
                    <given-names>Sapna P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Diab</surname>
                    <given-names>Adi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lucci</surname>
                    <given-names>Anthony</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9204-7161</contrib-id>
                  <name>
                    <surname>Prieto</surname>
                    <given-names>Victor G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0977-0912</contrib-id>
                  <name>
                    <surname>Davies</surname>
                    <given-names>Michael A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Allison</surname>
                    <given-names>James P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4658-055X</contrib-id>
                  <name>
                    <surname>Sharma</surname>
                    <given-names>Padmanee</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3438-7576</contrib-id>
                  <name>
                    <surname>Wargo</surname>
                    <given-names>Jennifer A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ariyan</surname>
                    <given-names>Charlotte</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1942-851X</contrib-id>
                  <name>
                    <surname>Tawbi</surname>
                    <given-names>Hussein A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Melanoma Medical Oncology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Medicine, </institution><institution>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, </institution></institution-wrap>New York, NY USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Department of Pathology, </institution><institution>The University of California San Francisco, </institution></institution-wrap>San Francisco, CA USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Surgical Oncology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX US </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Pathology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Immunology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Biostatistics, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Pathology, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Head and Neck Surgery, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Surgical Oncology, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Radiology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>26</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>26</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2022</year>
              </pub-date>
              <volume>611</volume>
              <issue>7934</issue>
              <fpage>155</fpage>
              <lpage>160</lpage>
              <history>
                <date date-type="received">
                  <day>1</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>20</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022, corrected publication 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously every 4 weeks) followed by surgery, and then ten doses of adjuvant combination therapy. The primary end point was pathologic complete response (pCR) rate<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. The combination resulted in 57% pCR rate and 70% overall pathologic response rate among 30 patients treated. The radiographic response rate using Response Evaluation Criteria in Solid Tumors 1.1 was 57%. No grade 3–4 immune-related adverse events were observed in the neoadjuvant setting. The 1- and 2-year recurrence-free survival rate was 100% and 92% for patients with any pathologic response, compared to 88% and 55% for patients who did not have a pathologic response (<italic>P</italic> = 0.005). Increased immune cell infiltration at baseline, and decrease in M2 macrophages during treatment, were associated with pathologic response. Our results indicate that neoadjuvant relatlimab and nivolumab induces a high pCR rate. Safety during neoadjuvant therapy is favourable compared to other combination immunotherapy regimens. These data, in combination with the results of the RELATIVITY-047 trial<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, provide further confirmation of the efficacy and safety of this new immunotherapy regimen.</p>
              </abstract>
              <abstract id="Abs2" abstract-type="web-summary">
                <p id="Par2">Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Melanoma</kwd>
                <kwd>Cancer immunotherapy</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s), under exclusive licence to Springer Nature Limited 2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Main</title>
              <p id="Par3">Patients with locoregionally advanced, resectable melanoma have a high risk of relapse and death from melanoma<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Specifically, patients with clinically detected nodal disease have a risk of melanoma-specific mortality that could be as high as 75%<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Although current adjuvant therapy decreases the risk of recurrence by about 50% (BRAF-targeted therapy hazard ratio (HR) 0.49, single agent PD-1 HR approximately 0.54)<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>, there has yet to be confirmation of the impact on overall survival<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. In an attempt to intensify therapy beyond single agent anti-PD-1, the Checkmate-915 trial was designed to investigate if the addition of ipilimumab to nivolumab in the adjuvant setting improved recurrence-free survival (RFS) compared to nivolumab alone. The combination of ipilimumab and nivolumab did not improve RFS (HR 0.92) and it significantly increased toxicity (grade 3–4 adverse events (AEs) 43%, compared to 23% for single agent anti-PD-1)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, indicating that intensification of adjuvant therapy with ipilimumab and nivolumab in the adjuvant setting is not the optimal approach for improving recurrence outcomes.</p>
              <p id="Par4">Neoadjuvant therapy offers several advantages over upfront surgery and adjuvant therapy, including potential for improvement in clinical outcomes and understanding molecular and immunological mechanisms of treatment response and resistance<sup><xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR13">13</xref></sup>. Additionally, neoadjuvant immunotherapy has demonstrated ability in preclinical models and in human samples to increase expansion of antigen-specific T cells due to the presence of tumour at the time of treatment compared to the expansion seen when the same immunotherapy is administered in the adjuvant setting<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. The neoadjuvant setting also offers the opportunity to intensify therapy with combinations for a short pre-operative course, allowing for a direct estimate of therapeutic efficacy and the ability to inform adjuvant therapy decisions.</p>
              <p id="Par5">One potential limitation of neoadjuvant immunotherapy is delay in curative-intent surgery if grade 3/4 immune-related adverse events (IRAEs) occur during treatment. For example, neoadjuvant administration of 2–3 doses of ipilimumab 3 mg kg<sup>−1</sup> + nivolumab 1 mg kg<sup>−1</sup> was associated with 73–90% grade 3/4 toxicities, which led to surgical delays in approximately 27% of patients<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. The OpACIN-NEO trial compared two doses of neoadjuvant therapy with different dosing strategies of ipilimumab and nivolumab. This study demonstrated that ipilimumab 1 mg kg<sup>−1</sup> with nivolumab 3 mg kg<sup>−1</sup> showed an at least equivalent pCR rate (57%) to the ipilimumab 3 mg kg<sup>−1 </sup>+ nivolumab 1 mg kg<sup>−1</sup> regimen (47%), but with a lower (20% versus 40%) incidence of grade 3/4 toxicities<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. These data highlight the goal of identifying new regimens that enhance pathologic responses and reduce risk of recurrence with improved toxicity profiles.</p>
              <p id="Par6">The lymphocyte-activation gene 3 (LAG-3) regulates an inhibitory immune checkpoint limiting T cell activity and is a marker for T cell exhaustion<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Relatlimab is a human IgG4 LAG-3-blocking monoclonal antibody that restores the effector function of exhausted T cells and has been investigated in both checkpoint inhibitor-naïve (NCT03470922)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> and refractory metastatic melanoma (NCT01968109)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. In the randomized phase 2/3 RELATIVITY-047 study, the combination of relatlimab with nivolumab in patients with treatment-naïve unresectable stage III or stage IV metastatic melanoma demonstrated significant improvement in progression-free survival compared to single agent nivolumab (HR 0.78 (95% confidence interval (CI), 0.64–0.94)). Moreover, the combination was well tolerated with 21.1% of patients experiencing grade 3/4 treatment-related AEs<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Given its efficacy and favourable toxicity profile, this combination therapy received US Food and Drug Administration approval for use in patients with metastatic melanoma on 18 March 2022.</p>
              <p id="Par7">Our group previously published our experience of a randomized, investigator-initiated clinical trial of either single agent nivolumab (240 mg intravenously every 2 weeks up to four doses) or nivolumab 1 mg kg<sup>−1</sup> with ipilimumab 3 mg  g<sup>−1</sup> (intravenously every 3 weeks up to three doses) in the neoadjuvant setting<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. In this trial, we concluded that although neoadjuvant single agent nivolumab was safe (8% grade 3/4 toxicities), its efficacy was modest (25% pCR rate). Although the combination of nivolumab with ipilimumab was effective with a 45% pCR rate, the toxicity was prohibitively high with 73% grade 3/4 toxicities<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Given these data and the early closure of the study due to suboptimal performance of both treatment arms, our team sought to evaluate new immunotherapy combinations with the intention of preserving pathologic response while minimizing toxicities. We opened a new arm to this existing prospective clinical trial to determine pCR rate, safety and efficacy of the relatlimab and nivolumab combination in patients with resectable clinical stage III or oligometastatic stage IV melanoma (Clinicaltrial.gov number NCT02519322) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Here we report the clinical results and immune profiling of this neoadjuvant therapy combination.<fig id="Fig1"><label>Fig. 1</label><caption><title>Study design.</title><p>Eligible patients receive two doses of relatlimab 160 mg with nivolumab 480 mg intravenously every 4 weeks (Q4W) in the neoadjuvant setting and then have repeat imaging for calculation of RECIST response. Surgery takes place at week 9 for evaluation of pathologic response. Patients receive up to ten doses of relatlimab 160 mg and nivolumab 480 mg every 4 weeks in the adjuvant setting and are followed for 2 years for evidence of recurrence. Blood and tumour are collected during screening, at weeks 3, 5 and at time of surgery at week 9. Blood is collected every 12 weeks (Q12W) in the adjuvant setting. ECOG PS, Eastern Cooperative Oncology Group Performance Status; RELA, relatlimab; NIVO, nivolumab; ORR, objective response rate; RECIST, Response Evaluation Criteria in Solid Tumors.</p></caption><graphic xlink:href="41586_2022_5368_Fig1_HTML" id="d33e600"/></fig></p>
            </sec>
            <sec id="Sec2">
              <title>Patient characteristics</title>
              <p id="Par8">From 19 September 2018 to 23 September 2020, 41 patients were consented and 30 passed screening evaluations and were treated at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. The most common reasons for screen failure included lack of resectable disease as determined by multidisciplinary review (<italic>n</italic> = 4 patients) and laboratory values outside the specified criteria (<italic>n</italic> = 3 patients) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Consort diagram and patient disposition.</title><p>A total of 41 patients were screened for protocol and there were 11 screen failures and 30 patients were eligible to initiate therapy. After completion of neoadjuvant therapy, one patient developed distant metastases and did not proceed to surgery. Twenty-nine patients proceeded to surgery and 17 patients (57%) achieved a pCR. Twenty-seven patients initiated adjuvant therapy and 15 went on to complete entire duration of treatment. path, pathologic.</p></caption><graphic xlink:href="41586_2022_5368_Fig2_HTML" id="d33e621"/></fig></p>
              <p id="Par9">The median age of treated patients was 60 (range 35–79) and 63% of patients were male (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>). Melanoma clinical stage was 60% stage IIIB, 26% IIIC, 7% IIID and 7% M1A by the American Joint Committee on Cancer 8th edition criteria<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Thirty-three per cent of patients had de novo clinical stage III or oligometastatic stage IV melanoma, and 67% had prior melanoma surgery. Only 17% of patients had <italic>BRAF-</italic>mutated melanoma, probably due to enrolment on a competing neoadjuvant trial specific for patients with <italic>BRAF-</italic>mutated disease. Only one patient had prior systemic therapy (BRAF and MEK inhibition). The median target lesion sum of diameters was 26 mm (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
            </sec>
            <sec id="Sec3">
              <title>Patient disposition</title>
              <p id="Par10">Of the 30 treated patients, 29 were able to receive the planned two doses of neoadjuvant relatlimab and nivolumab. One patient received only one dose due to asymptomatic troponin elevations with concern for myocarditis, which was eventually determined to not be attributable to neoadjuvant immunotherapy after the patient underwent myocardial biopsy and was able to proceed safely to surgery. One patient did not proceed to surgery due to development of distant metastatic disease during neoadjuvant therapy. Of the 29 patients that underwent surgery, 27 patients proceeded to surgery as scheduled at week 9; one patient was delayed due to the aforementioned myocarditis toxicity concern and one patient was delayed due to SARS-CoV2 pandemic-related hospital surgery restrictions. Twenty-seven patients proceeded with adjuvant therapy and two patients elected to not proceed with adjuvant therapy due to suboptimal pathologic and imaging response. Fifty-six per cent of patients completed the entire duration of protocol therapy, 33% of patients discontinued adjuvant therapy due to toxicity and 11% of patients withdrew consent during adjuvant therapy (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Currently, all patients are off protocol therapy.</p>
            </sec>
            <sec id="Sec4">
              <title>Clinical activity</title>
              <p id="Par11">Of the 30 patients enroled, 29 patients underwent surgery (97%), 17 (57%; 95% CI, 37–75%) achieved pCR, two (7%) near pCR (defined as greater than 0% but less than or equal to 10% viable tumour), two (7%) partial pathologic response (pPR; defined as greater than 10% to less than or equal to 50% viable tumour) and eight (27%) no pathologic response (pNR; defined as greater than 50% viable tumour) (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). A major pathologic response (pCR + near pCR) was achieved in 63% of patients and any pathologic response (pCR + near pCR + pPR) in 70% of patients<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.<fig id="Fig3"><label>Fig. 3</label><caption><title>Response data and long-term outcomes.</title><p><bold>a</bold>, Breakdown of pathologic responses for the 29 patients who underwent surgery as interpreted by the guidelines of the INMC. Result details (values in chart rounded): no operation, 1 of 30 patients (3.33%);pCR, 17 of 30 patients (56.67%); near pCR, 2 of 30 patients (6.67%);pPR, 2 of 30 patients (6.67%);pNR, 8 of 30 patients (26.67%). <bold>b</bold>, Waterfall plot of neoadjuvant response as per RECIST 1.1 criteria with colour coding indicating pathologic response. pCR indicates lack of viable tumour. Near pCR indicates greater than 0% but less than or equal to 10% viable tumour, pPR is greater than 10% to less than or equal to 50% viable tumour and pNR is greater than 50% viable tumour. <bold>c</bold>, Probability of being relapse-free based on any pathologic response versus no pathologic response. <bold>d</bold>, Overall survival curves for the entire cohort.</p></caption><graphic xlink:href="41586_2022_5368_Fig3_HTML" id="d33e677"/></fig></p>
              <p id="Par12">The radiographic overall response rate was 57% (all partial responses (PRs); 33% had stable disease (SD) and 10% had progressive disease (PD)(Fig. <xref rid="Fig3" ref-type="fig">3b</xref>)) in the intention-to-treat population. Pathologic response was frequently disconcordant with radiographic response at 8 weeks. For example, of the 19 patients who achieved major pathologic response (pCR and near pCR), one patient had radiographic PD, three had SD and 15 had PR. Of the eight patients with pNR, only one had radiographic PD and seven had SD. In the 16 patients with tumour sum of diameters at the median or higher (at least 26 mm), there was a mix of Response Evaluation Criteria in Solid Tumors (RECIST; 6% PD, 38% SD, 56% PR) and pathologic responses (38% pNR, 6% pPR, 6% near pCR, 50% pCR), indicating that baseline tumour burden did not correlate directly with pathologic or radiographic response.</p>
              <p id="Par13">With a median follow-up of 24.4 months (range 7.1–34.6 months) for the 30 treated patients, 1- and 2-year event-free survival rates (time from treatment initiation to recurrence in all patients) were 90% and 81%, respectively (Extended Data Fig. <xref rid="Fig5" ref-type="fig">1</xref>). The 1- and 2-year RFS rates (time from surgery to recurrence in patients that underwent surgery) were 97% and 82%, respectively (Extended Data Fig. <xref rid="Fig6" ref-type="fig">2a</xref>). The 1- and 2-year RFS rates were 100% and 91% for patients with pCR, compared to 92% and 69% for those without pCR (<italic>P</italic> = 0.10) (Extended Data Fig. <xref rid="Fig6" ref-type="fig">2b</xref>). The 1- and 2-year RFS rates were 100% and 92% for patients with any pathologic response, compared to 88% and 55% for those without a pathologic response (<italic>P</italic> = 0.005) (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). The 1- and 2-year overall survival rates for all patients were 93% and 88% (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>).</p>
              <p id="Par14">Of the three patients with RECIST PD to neoadjuvant therapy, one patient developed distant metastases (brain) and did not undergo surgery. The two other RECIST PD patients appeared to progress locally in the involved nodal basin only, and complete surgical resection was achieved for both. One of these patients did not proceed with adjuvant therapy due to pNR and patient/physician decision; the other achieved a pCR, proceeded with adjuvant therapy and completed protocol therapy without disease recurrence (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Two patients (both pNR) experienced local recurrence in soft tissue adjacent to site of prior surgical resection at 3 and 14 months after completion of all ten doses of adjuvant therapy. One patient with pCR reportedly experienced unconfirmed disease progression in the brain and passed away 14 months after surgery.</p>
            </sec>
            <sec id="Sec5">
              <title>Safety</title>
              <p id="Par15">There were no grade 3/4 IRAEs during the 8 weeks of neoadjuvant therapy (Extended Data Table <xref rid="Tab2" ref-type="table">2</xref>). Twenty-six per cent of patients developed grade 3/4 IRAEs in the adjuvant setting (from week 9 and beyond) (Extended Data Table <xref rid="Tab2" ref-type="table">2</xref>). Overall, 33% of patients elected to discontinue adjuvant therapy due to any toxicity (most commonly transaminitis). Although there were asymptomatic troponin elevations, no patients experienced symptomatic troponin elevations, myocarditis or other cardiac toxicity attributable to study medications as assessed by cardiology consultation. The most frequent IRAE was secondary adrenal insufficiency (23%), with none of the patients experiencing adrenal recovery to date.</p>
            </sec>
            <sec id="Sec6">
              <title>Correlative studies</title>
              <p id="Par16">Biomarker analysis focused on characterizing immune cell subsets in the tumour microenvironment and peripheral blood was performed by mass cytometry (CyTOF) and flow cytometry. LAG-3 and PD-1 levels in baseline tumour samples did not correlate with pathologic response (Extended Data Fig. <xref rid="Fig7" ref-type="fig">3</xref>). In tumours, the frequency of CD45<sup>+</sup> cells was higher in pretreatment samples of responders, defined as patients with less than 50% tumour viability at surgery, compared to pretreatment samples of non-responders (NRs; greater than or equal to 50% tumour viability) (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>) by CyTOF. Unsupervised clustering identified an effector CD8<sup>+</sup> T cell subset (CD8<sup>+</sup>CD45RO<sup>low</sup>) and a memory CD4<sup>+</sup> T cell subset (CD4<sup>+</sup>CD45RO<sup>+</sup>TCF7<sup>+</sup>CD28<sup>+</sup>BTLA<sup>+</sup>TIGIT<sup>+</sup>) that were increased in posttreatment tumour specimens versus pretreatment in patients with favourable response (Fig. <xref rid="Fig4" ref-type="fig">4b,c</xref>). The increases in these cell populations were not appreciated in the NR patient group, although it should be noted that the number of evaluable specimens was low in this group (Fig. <xref rid="Fig4" ref-type="fig">4b,c</xref>). By contrast, the frequency of an M2-like macrophage subset decreased in tumours after treatment in patients with favourable response (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4a</xref>). In blood, there was a trend for increased EOMES<sup>+</sup>CD8<sup>+</sup> T cells in patients with favourable versus non-favourable response after treatment, with largest differences seen at week 5 posttreatment (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4b</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Correlative analyses in tumour specimens.</title><p>Tumour tissue samples harvested from patients at baseline, and post relatlimab and nivolumab treatment were analysed in a single experiment by CyTOF (<bold>a</bold>–<bold>c</bold>). <bold>a</bold>, Frequency of CD45<sup>+</sup> cells was assessed through manual gating. <bold>b</bold>, Frequency of an effector CD8<sup>+</sup> T cell subset (CD3<sup>+</sup>CD8<sup>+</sup>CD45RO<sup>low</sup>) in unsupervised clustering is shown. <bold>c</bold>, Frequency of a memory CD4<sup>+</sup> subset (CD45RO<sup>+</sup>ICOS<sup>+</sup> TCF7<sup>+</sup>BTLA<sup>+</sup>CD28<sup>+</sup>TIGIT<sup>+</sup>) was determined by unsupervised clustering. Data shown in <bold>a</bold>–<bold>c</bold> are mean ± s.d., and <italic>n</italic> values are indicated in the figure. <italic>P</italic> values shown in each graph were calculated by two-tailed unpaired <italic>t</italic>-test, with no multiple comparisons. Red indicates pathologic responders; blue, non-responders. CyTOF, mass cytometry; NR, non-responder; R, responder; wk, week.</p><p><xref rid="MOESM4" ref-type="media">Source data</xref>.</p></caption><graphic xlink:href="41586_2022_5368_Fig4_HTML" id="d33e842"/></fig></p>
            </sec>
            <sec id="Sec7" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par17">In patients with resectable clinical stage III or oligometastatic stage IV melanoma, neoadjuvant relatlimab with nivolumab resulted in high pCR rate (57%; 95% CI, 37–75%) and improvement in the 2-year RFS rate in patients who achieved any pathologic response compared to those without a pathologic response (<italic>P</italic> = 0.005). The lower limit CI (37%) exceeded the minimum target of 30% in the study design. This regimen was tolerated well in the neoadjuvant setting, with 26% grade 3 toxicities noted with continued dosing in the adjuvant setting. In patients with pathologic response, increased immune cell infiltration was identified at baseline and decreased M2 macrophages were demonstrated over the course of neoadjuvant therapy.</p>
              <p id="Par18">The first two randomized arms of this trial evaluated both single agent nivolumab and the combination of ipilimumab 3 mg kg<sup>−1</sup> and nivolumab 1 mg kg<sup>−1</sup>. Twenty-seven per cent of patients treated with ipilimumab 3 mg kg<sup>−1</sup> and nivolumab 1 mg kg<sup>−1</sup> required surgical delays of 1–10 weeks due to need for steroids and prolonged steroid taper<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. With no grade 3/4 IRAEs observed in the neoadjuvant setting and no confirmed toxicity-related surgical delays, the combination of nivolumab and relatlimab now provides complementary information and demonstrates a highly effective regimen with manageable toxicities in the neoadjuvant setting.</p>
              <p id="Par19">Although there were no grade 3/4 IRAEs in the neoadjuvant setting, 26% grade 3/4 toxicities were experienced in the adjuvant setting. The most common IRAE observed was secondary adrenal insufficiency. As 33% of patients discontinued therapy before the planned full year of treatment, due to toxicity, it raises questions of whether continued dosing in the adjuvant setting is necessary following pathologic response to neoadjuvant therapy. Additionally, none of the patients who stopped therapy early due to toxicity have experienced a recurrence event. There is not clear consensus on the need for the adjuvant phase of therapy within neoadjuvant trials, with completed or ongoing trials including complete omission of any adjuvant therapy, use of adjuvanttherapy only in poor responders or adjuvant therapy to complete 1 year of treatment<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref></sup>, Additionally, the use of adjuvant therapy can certainly affect the RFS and can cloud the interpretation of neoadjuvant therapy data. Understanding the contribution of adjuvant immunotherapy following immunotherapy in the neoadjuvant setting to clinical benefit remains an active area of research interest.</p>
              <p id="Par20">The historic dogma in neoadjuvant chemotherapy emphasized pCR as the critical end point correlating with the most durable clinical outcomes<sup><xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref></sup>. This was similarly appreciated in the International Neoadjuvant Melanoma Consortium (INMC) pooled analysis of neoadjuvant BRAF/MEK inhibitor use in patients with clinical stage III melanoma, showing that achieving a pCR, but not a pPR, correlated with improved RFS<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. Although the pCR end point may still be appropriate for neoadjuvant chemotherapy or molecularly targeted therapy, our data provide further evidence that in the context of neoadjuvant immunotherapy in melanoma, any pathologic response (less than 50% viable tumour) is associated with favourable long-term clinical outcomes (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>)<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. Similar patterns of improved clinical responses with any pathologic response are being appreciated in neoadjuvant immunotherapy trials across solid tumours<sup><xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref></sup>.</p>
              <p id="Par21">Although baseline LAG-3 and PD-1 levels in tumour samples did not correlate with response, we observed increased frequencies of memory CD4<sup>+</sup> and effector CD8<sup>+</sup> T cells in the posttreatment tumour specimens of patients with favourable treatment response. These findings are concordant with previous studies in which responses to anti-PD-1 were associated with higher CD8<sup>+</sup> T cells<sup><xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. Furthermore, we observed a reduction in M2-like macrophages with treatment only in the patients that achieved a pathologic response, possibly serving as a target to further improve responsiveness to this regimen, and/or to further evaluate in other studies of nivolumab plus relatlimab<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Analysis of longitudinal peripheral blood specimens by flow cytometry revealed higher frequency of EOMES<sup>+</sup>CD8<sup>+</sup> T cells in posttreatment samples of responding patients, suggesting CD8<sup>+</sup> T cells expressing EOMES could contribute to tumour regression. This supports a potentially critical role of EOMES for antitumour activity of CD8<sup>+</sup> T cells, as previously described<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. These data indicate that a higher frequency of total immune cell infiltration, as well as increased specific effector CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets, with a concomitant decrease in suppressive myeloid cells in the tumour microenvironment, correlate with clinical response to this regimen in the neoadjuvant setting. It should be noted that the number of usable samples in the NR patients was low, which limits comparative correlative analyses in this study.</p>
              <p id="Par22">We acknowledge that the study is limited by its small sample size and that these results are preliminary, based on findings at two academic research institutions. However, the cohort evaluated in this study (<italic>n</italic> = 30) is largely similar to the individual arms in the OpACIN-NEO study and to other single-arm neoadjuvant immunotherapy trials<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR26">26</xref></sup>. With a median follow-up of 24 months, we also acknowledge that additional follow-up is needed to fully assess clinical impact and the durability of responses. However, this initial data is encouraging, and the pooled analyses of melanoma neoadjuvant trials support the importance of pathologic response rates as an early predictor of durable benefit<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Similarly, additional translational studies beyond the scope of this manuscript are planned, including RNA sequencing for broad assessment of additional immune signatures and populations that have been implicated in immunotherapy resistance<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>.</p>
              <p id="Par23">In summary, neoadjuvant relatlimab and nivolumab is a highly active regimen that achieves a 70% pathologic response rate with a favourable safety profile in patients with high-risk, resectable clinical stage III or oligometastatic stage IV melanoma. These data are complementary to the RELATIVITY-047 study in patients with unresectable metastatic melanoma, and together further support the promise of this new combination immunotherapy regimen in this disease.</p>
            </sec>
            <sec id="Sec8" sec-type="materials|methods">
              <title>Methods</title>
              <sec id="Sec9">
                <title>Patients</title>
                <p id="Par24">Eligible patients were 18 years or older with clinical stage III or oligometastatic (less than three organ sites with metastases) stage IV melanoma with lesions that were measurable by RECIST 1.1 (ref. <sup><xref ref-type="bibr" rid="CR32">32</xref></sup>). Resectable clinical stage III melanoma was defined as clinically detectable, RECIST-measurable lymph node disease with or without regional in-transit or satellite metastases and without distant metastases. Resectability of stage III and IV disease was verified via multidisciplinary conference. Patients with recurrent melanoma or de novo American Joint Committee on Cancer 8th edition<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> clinical stage III or IV disease were considered eligible, and all melanoma subtypes, including uveal, mucosal or acral, were eligible for enrolment. All patients had Eastern Cooperative Oncology Group performance status of 0 or 1 with normal organ function and no contra-indication to surgery. Patients requiring active immunosuppressive therapy, or who had active autoimmune or infectious disease, or with uncontrolled cardiovascular disease or ongoing concurrent malignancy were excluded.</p>
              </sec>
              <sec id="Sec10">
                <title>Study design</title>
                <p id="Par25">This investigator-initiated, prospective study was conducted at two academic medical centres in the United States. Patients received two intravenous fixed doses of relatlimab 160 mg with nivolumab 480 mg at 4-week intervals. Surgery was planned 9 weeks after treatment initiation. Patients were given up to ten doses of the combination starting 4–6 weeks after surgery to complete a total of 12 doses. Patients were followed for 2 years postsurgery for any evidence of disease recurrence (study design details are provided in Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p>
                <p id="Par26">The primary end point was determination of pCR (defined as no viable tumour upon pathologic evaluation at surgery) rate<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. For this exploratory biomarker study, a pathologic response rate of 30% was suggested for patients treated with this combination. Assuming this true pCR rate, the probability of at least 5 out of 30 patients experiencing a pCR is 0.97. Secondary end points included RECIST 1.1 overall response rate, safety, RFS, event-free survival, overall survival and correlation of immune profiling with response.</p>
                <p id="Par27">All patients were monitored for AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v.4.03 (ref. <sup><xref ref-type="bibr" rid="CR33">33</xref></sup>). Due to concern for myocarditis based on prior relatlimab studies<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>, patients were required to have cardiac troponin testing, in addition to assessment of blood counts, electrolytes, liver and kidney function before each scheduled infusion. All patients underwent baseline tumour staging (either computed tomography or positron-emission tomography-computed tomography of body and magnetic resonance imaging of brain) within 28 days of treatment initiation and again during week 8 for determination of RECIST response. Scans were performed every 3 months in the postoperative setting for up to 2 years after surgery. Core needle biopsy was performed within 28 days of treatment initiation and at weeks 3 and 5 for correlative research. Blood was collected at time of treatment initiation, weeks 3, 5, 9 and then every 12 weeks in the postoperative setting for up to 2 years (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Surgical resection was completed at week 9 per institutional standards and per the guidelines of the INMC<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. Pathologic review of surgical resection specimens was performed by a small group of dermatopathologists who assessed the specimens according to the practices outlined by the INMC<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. pCR was defined as no viable tumour, near pCR as greater than 0% but less than or equal to 10% viable tumour, pPR as greater than 10% to less than or equal to 50% viable tumour and pNR as greater than 50% viable tumour.</p>
              </sec>
              <sec id="Sec11">
                <title>Study oversight</title>
                <p id="Par28">The study was conducted in accordance with the clinical trial protocol and Good Clinical Practices Guidelines as defined by the International Conference on Harmonization and the Declaration of Helsinki. The study was approved by the institutional review boards of MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. All patients provided informed consent for participation in the clinical trial. The study was designed by investigators at MD Anderson Cancer Center and the manuscript was written by the authors in its entirety. Trial monitoring was by the Investigational New Drugs office at MD Anderson Cancer Center. Study drugs were supplied by Bristol-Myers Squibb.</p>
              </sec>
              <sec id="Sec12">
                <title>Statistical analyses</title>
                <p id="Par29">RFS time was computed from surgery date to date of progression/recurrence or death (if died without progression/recurrence). Event-free survival time was computed from start of treatment to date of progression/recurrence or death (if died without progression/recurrence). Patients alive at the last follow-up date who did not experience progression/recurrence were censored. Patients who died without experiencing progression/recurrence were censored. Overall survival time was computed from start of neoadjuvant therapy to last known vital status. Patients alive at the last follow-up date were censored. The Kaplan–Meier method was used to estimate the outcome measures, and group differences were evaluated using the log-rank test. All statistical analyses were performed using SAS v.9.4 for Windows.</p>
              </sec>
              <sec id="Sec13">
                <title>Correlative studies</title>
                <p id="Par30">Blood and tumour were collected at the timepoints shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Cells were isolated and prepared from peripheral blood and tumour tissues for flow cytometry and CyTOF analyses as per the specifications below.</p>
                <sec id="Sec14">
                  <title>Isolation and preparation of cells from peripheral blood and tissues</title>
                  <p id="Par31">Whole blood was collected in tubes containing sodium heparin (BD Vacutainer), resuspended in phosphate-buffered saline (PBS), layered atop Ficoll (StemCell Technologies) and centrifuged at 800<italic>g</italic> for 25 min. The interface peripheral blood mononuclear cells (PBMCs) were harvested and washed twice with PBS and centrifuged at 500<italic>g</italic> for 10 min. Fresh tumour tissue was dissociated with GentleMACS system (Miltenyi Biotec). PBMC and tumour specimens destined for CyTOF analysis were stained for viability with 5 μmol l<sup>−1</sup> cisplatin (Fluidigm, now Standard Biotools) in PBS containing 1% bovine serum albumin (BSA) and then washed three times. All specimens were resuspended in AB serum with 10% (vol/vol) dimethyl sulfoxide for storage in liquid nitrogen until downstream assays were performed.</p>
                </sec>
              </sec>
              <sec id="Sec15">
                <title>Flow cytometry staining and analysis</title>
                <p id="Par32">Flow cytometry analysis was performed on PBMCs (see Extended Data Table <xref rid="Tab3" ref-type="table">3</xref> for antibodies used in flow cytometry). Single-cell suspensions were stained with 16 fluorescent primary antibodies and live/dead dye. Specimens were analysed using the BD LSRFortessa ×20 cytometer and BD FACSDiva acquisition software v.8.0.1 (BD Biosciences), and downstream analyses were performed manually using FlowJo software v.10.5.3 (BD). See Extended Data Fig. <xref rid="Fig9" ref-type="fig">5</xref> for flow cytometry sequential gating/sorting strategies.</p>
              </sec>
              <sec id="Sec16">
                <title>Mass cytometry staining and analysis</title>
                <p id="Par33">CyTOF analyses were performed on tumour specimens as well as PBMCs (see Extended Data Table <xref rid="Tab4" ref-type="table">4</xref> for antibodies used in CyTOF analysis). Single-cell suspensions were assayed with 41 antibodies, plus Ir DNA-intercalator and cisplatin. Antibodies were either purchased preconjugated from Fluidigm or purchased purified and conjugated in-house using MaxPar X8 Polymer kits (Fluidigm, now Standard Biotools). Briefly, samples were thawed and stained with cell surface antibodies in PBS containing 5% goat serum and 1% BSA for 30 min at 4 °C. Samples were then washed in PBS containing 1% BSA, fixed and permeabilized according to the instructions of the manufacturers using the FoxP3 staining buffer set (eBioscience), before being incubated with intracellular antibodies in permeabilization buffer for 30 min at 4 °C. Samples were washed and incubated in Ir intercalator (Fluidigm, now Standard Biotools) and stored at 4 °C until acquisition, generally within 12 h. Immediately before acquisition, samples were washed and resuspended in water containing EQ 4 element beads (Fluidigm, now Standard Biotools). Samples were acquired on a Helios mass cytometer (Fluidigm, now Standard Biotools).</p>
                <p id="Par34">FCS files were preprocessed in R (R Foundation for Statistical Computing (<ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link>)) using a CyTOF package (Premessa, Parker Institute for Cancer Immunotherapy (<ext-link ext-link-type="uri" xlink:href="https://github.com/ParkerICI">https://github.com/ParkerICI</ext-link>)) and gated manually in FlowJo (BD). Data were then exported as FCS files for downstream analysis and arcsinh transformed using a coefficient of 5 [x_transformed = arcsinh(x/5)]. To visualize the high-dimensional data in two dimensions, the t-Distributed Stochastic Neighbor Embedding dimension reduction algorithm was applied, using all channels besides those used to manually gate the population of interest (for example, CD45 or CD3). Clustering analysis was performed in R using the FlowSOM and ConsensusClusterPlus packages<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>.</p>
              </sec>
              <sec id="Sec17">
                <title>Graphics and statistics</title>
                <p id="Par35">Graphs were created and statistical analyses performed using GraphPad Prizm v.9.2 (GraphPad Software, LLC).</p>
              </sec>
              <sec id="Sec18">
                <title>Reporting summary</title>
                <p id="Par36">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
              </sec>
            </sec>
            <sec id="Sec19" sec-type="materials|methods">
              <title>Online content</title>
              <p id="Par37">Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information, details of author contributions and competing interests, and statements of data and code availability are available at 10.1038/s41586-022-05368-8.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <sec id="Sec21">
                <title>Supplementary information</title>
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41586_2022_5368_MOESM1_ESM.pdf">
                      <label>Supplementary Information</label>
                      <caption>
                        <p>This file contains the Protocol.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM2">
                    <media xlink:href="41586_2022_5368_MOESM2_ESM.pdf">
                      <caption>
                        <p>Reporting Summary</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM3">
                    <media xlink:href="41586_2022_5368_MOESM3_ESM.pdf">
                      <caption>
                        <p>Peer Review File</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
              <sec id="Sec22">
                <title>Source data</title>
                <p>
                  <supplementary-material content-type="local-data" id="MOESM4">
                    <media xlink:href="41586_2022_5368_MOESM4_ESM.xlsx">
                      <caption>
                        <p>Source Data Fig. 4 and Extended Data Figs. 2 and 3.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <app-group>
              <app id="App1">
                <sec id="Sec20">
                  <title>Extended data figures and tables</title>
                  <p id="Par40">
                    <fig id="Fig5">
                      <label>Extended Data Fig. 1</label>
                      <caption>
                        <p>Probability of being event-free for all patients who received study treatment.</p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Fig5_ESM" id="d33e1195"/>
                    </fig>
                  </p>
                  <p id="Par41">
                    <fig id="Fig6">
                      <label>Extended Data Fig. 2</label>
                      <caption>
                        <title>Probability of being recurrence-free.</title>
                        <p><bold>A</bold>) Probability of being recurrence-free for all patients who underwent surgery. <bold>B</bold>) Probability of being recurrence-free based on pathologic complete response versus non-pathologic complete response (<italic>P</italic> = 0.10).</p>
                        <p>
                          <xref rid="MOESM4" ref-type="media">Source data</xref>
                        </p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Fig6_ESM" id="d33e1220"/>
                    </fig>
                  </p>
                  <p id="Par42">
                    <fig id="Fig7">
                      <label>Extended Data Fig. 3</label>
                      <caption>
                        <title>PD-1 and LAG-3 levels in baseline tumour.</title>
                        <p>Tumour infiltrating immune cells were assayed via CyTOF and analysed by manual gating for frequency of <bold>A</bold>) PD-1 and <bold>B</bold>) LAG-3 levels in T cells prior to treatment. Red, pathologic responders; blue, pathologic non-responders. Data are mean +/− SD; <italic>P</italic> values where shown were determined by two-tailed unpaired <italic>t</italic>-test, with no multiple comparisons. <italic>n</italic> values for each group/timepoint are indicated in each graph.</p>
                        <p>
                          <xref rid="MOESM4" ref-type="media">Source data</xref>
                        </p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Fig7_ESM" id="d33e1252"/>
                    </fig>
                  </p>
                  <p id="Par43">
                    <fig id="Fig8">
                      <label>Extended Data Fig. 4</label>
                      <caption>
                        <title>M2-like macrophages in tumour and EOMES+ CD8+ T cells in blood.</title>
                        <p><bold>A</bold>) Frequency of an M2-like macrophage subset (CD68+ HLA-DR+ CD14+ VISTA+ CD163+ CD45RO+ PD-L1+) was determined by unsupervised clustering of CyTOF data from a single experiment. <bold>B</bold>) Frequency of EOMES+ CD8+ T cells. PBMCs isolated from blood samples were analysed by flow cytometry from a single experiment. Data are mean +/− SD; <italic>P</italic> value was determined by two-tailed unpaired <italic>t</italic>-test, with no multiple comparisons. <italic>n</italic> values for each group/timepoint are indicated in each graph. Red indicates pathologic responders; blue, non-responders.</p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Fig8_ESM" id="d33e1278"/>
                    </fig>
                  </p>
                  <p id="Par44">
                    <fig id="Fig9">
                      <label>Extended Data Fig. 5</label>
                      <caption>
                        <title>Gating schema for manual analysis of CyTOF data from tumour and blood specimens.</title>
                        <p><bold>A</bold>) Tumours were mechanically dissociated and cells were stained with immune cell-specific antibodies. Specimens were assayed on the Helios mass cytometer via CyTOF Software. Cytometer data were then prepared for manual and unsupervised analyses via FlowJo software. Major cell populations were identified manually and reported. An example of one patient specimen is shown above for reference. <bold>B</bold>) Gating schema for flow cytometric analysis of blood specimens. Peripheral blood mononuclear cells from patient specimens were stained along with FMO (fluorescence minus one) controls and assayed via a BD LSRFortessa cytometer and BD FACSDiva acquisition software. Data were analysed via FlowJo software as described above. Briefly, live CD3+ singlets were identified and gated into T cell lineages, and those lineages analysed for frequency of each of eight phenotypic markers (BCL6, BLIMP1, CD27, CD28, cMYC, EOMES, ICOS, Ki67) as defined by FMO (fluorescence minus one) specimens. An example of one phenotypic marker (EOMES) in one patient specimen is shown above for reference.</p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Fig9_ESM" id="d33e1295"/>
                    </fig>
                  </p>
                  <p id="Par45">
                    <table-wrap id="Tab1">
                      <label>Extended Data Table 1</label>
                      <caption>
                        <p>Baseline patient characteristics</p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Tab1_ESM" id="d33e1305">
                        <caption>
                          <p>Baseline patient characteristics</p>
                        </caption>
                      </graphic>
                    </table-wrap>
                  </p>
                  <p id="Par46">
                    <table-wrap id="Tab2">
                      <label>Extended Data Table 2</label>
                      <caption>
                        <p>Immune-related adverse events during neoadjuvant and adjuvant therapy</p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Tab2_ESM" id="d33e1318">
                        <caption>
                          <p>Immune-related adverse events during neoadjuvant and adjuvant therapy</p>
                        </caption>
                      </graphic>
                    </table-wrap>
                  </p>
                  <p id="Par47">
                    <table-wrap id="Tab3">
                      <label>Extended Data Table 3</label>
                      <caption>
                        <p>Antibodies for flow cytometry analysis</p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Tab3_ESM" id="d33e1331">
                        <caption>
                          <p>Antibodies for flow cytometry analysis</p>
                        </caption>
                      </graphic>
                    </table-wrap>
                  </p>
                  <p id="Par48">
                    <table-wrap id="Tab4">
                      <label>Extended Data Table 4</label>
                      <caption>
                        <p>Antibodies for CyTOF analysis</p>
                      </caption>
                      <graphic position="anchor" xlink:href="41586_2022_5368_Tab4_ESM" id="d33e1344">
                        <caption>
                          <p>Antibodies for CyTOF analysis</p>
                        </caption>
                      </graphic>
                    </table-wrap>
                  </p>
                </sec>
              </app>
            </app-group>
            <fn-group>
              <fn>
                <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
              <fn>
                <p>These authors contributed equally: Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton</p>
              </fn>
              <fn>
                <p>These authors jointly supervised this work: Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi</p>
              </fn>
              <fn>
                <p>
                  <bold>Change history</bold>
                </p>
                <p>3/9/2023</p>
                <p>A Correction to this paper has been published: 10.1038/s41586-023-05892-1</p>
              </fn>
            </fn-group>
            <sec>
              <title>Extended data</title>
              <p>is available for this paper at 10.1038/s41586-022-05368-8.</p>
            </sec>
            <sec>
              <title>Supplementary information</title>
              <p>The online version contains supplementary material available at 10.1038/s41586-022-05368-8.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant award number P50CA221703. We would like to acknowledge the Melanoma Informatics, Tissue Resource and Translational Pathology Core at The University of Texas MD Anderson Cancer Center. This project was supported by the generous philanthropic contributions to The University of Texas MD Anderson Cancer Moon Shots Program. M. Postow is supported by Cancer Center Support Grant P30 CA08748 from the National Institutes of Health/National Cancer Institute. C.A. is supported by a pilot grant from the Parker Institute for Cancer Immunotherapy at MSKCC.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>R.N.A., E.M.B., M.A.D., J.A.W. and H.A.T. contributed to the conception and design of the study in collaboration with Bristol-Myers Squibb. R.N.A., M. Postow, M.I.R., I.C.G., L.S., J.L.M., M.K.W., J.E.G., J.E.L., R.P.G., E.Z.K., S.B.F., A.B.-W., A.N.S., M.C., D.C., E.K.B., D.B., P.M., S.P.P., A.D., A.L., M.A.D., J.A.W., C.A. and H.A.T. recruited and/or treated patients and gathered clinical data on efficacy and safety. D.R.M. analysed the clinical data and performed statistical analyses. F.D., C.N., A.G., X.Z., J.P.A. and P.S. performed biomarker analyses. M.T.T., C.T.-C., K.B. and V.G.P. performed pathologic analyses. B.R.K. and M. Patnana performed radiologic analyses. All authors interpreted the data. All authors had access to all the data in the study, participated in developing or reviewing the manuscript and provided final approval to submit the manuscript for publication.</p>
            </notes>
            <notes notes-type="peer-review">
              <title>Peer review</title>
              <sec id="FPar1">
                <title>Peer review information</title>
                <p id="Par38"><italic>Nature</italic> thanks Mark Faries, Antoni Ribas and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. <xref rid="MOESM3" ref-type="media">Peer reviewer reports</xref> are available.</p>
              </sec>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>Data supporting the findings of this study have been provided to <italic>Nature</italic> through direct deposition.</p>
            </notes>
            <notes id="FPar2" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par39">R.N.A.: research funding from Bristol-Myers Squibb, Iovance, Merck and Novartis; consulting role for Bristol-Myers Squibb, Iovance and Novartis. M. Postow: consulting fees from Aduro, Array BioPharma, Bristol-Myers Squibb, Eisai, Incyte, Merck, NewLink Genetics, Novartis and Pfizer; honoraria from Bristol-Myers Squibb and Merck; institutional support from Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Infinity, Merck, Novartis and RGenix. M.I.R.: clinical research funding from Amgen; consulting/advisory board member role for Amgen, Castle BioSciences, Merck and Novartis. I.C.G.: research funding from Bristol-Myers Squibb, Merck and Pfizer; consulting role for Bristol-Myers Squibb and Novartis. J.L.M.: honoraria for Bristol-Myers Squibb and Roche; consultant for Merck. M.K.W.: advisory boards for Adagene, Bristol-Myers Squibb, Castle Biosciences, EMD-Serono, ExiCure, Merck, Pfizer and Regeneron. J.E.G.: consultant and/or advisory role; Merck and Regeneron. A.N.S.: research funding from Bristol-Myers Squibb, Checkmate Pharmaceuticals, Foghorn Therapeutics, Immunocore, Novartis, Pfizer, Polaris, Targovax and Xcovery; advisory board for Bristol-Myers Squibb, Immunocore and Novartis. A.D.: research funding from Apexigen, Idera and Nektar; consulting for Apexigen, Idera, Memgen, Nektar and Pfizer. S.P.P.: research funding from Bristol-Myers Squibb, Ideaya and Provectus; consulting honoraria from Cardinal Health, Castle Biosciences and Merck. M.A.D.: consultant to ABM Therapeutics, Apexigen, Array, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Pfizer, Roche/Genentech, Novartis, Sanofi-Aventis and Vaccinex; PI of research grants to GlaxoSmithKline, MD Anderson by Roche/Genentech, Merck, Myriad, Oncothyreon and Sanofi-Aventis. J.P.A.: consulting or stock ownership or advisory board for Achelois, Adaptive Biotechnologies, Apricity, BioAtla, BioNTech, Candel Therapeutics, Codiak, Dragonfly, Earli, Enable Medicine, Hummingbird, ImaginAb, Jounce, Lava Therapeutics, Lytix, Marker, PBM Capital, Phenomic AI, Polaris Pharma, Time Bioventures, Trained Therapeutix and Venn Biosciences. P.S.: consulting or stock ownership or advisory board for Achelois, Adaptive Biotechnologies, Affini-T, Apricity, BioAtla, BioNTech, Candel Therapeutics, Catalio, Codiak, Constellation, Dragonfly, Earli, Enable Medicine, Glympse, Hummingbird, ImaginAb, Infinity Pharma, Jounce, JSL Health, Lava Therapeutics, Lytix, Marker, MedImmune, Oncolytics, PBM Capital, Phenomic AI, Polaris Pharma, Sporos, Time Bioventures, Trained Therapeutix and Venn Biosciences. J.A.W.: compensation for speaker’s bureau and honoraria from Bristol-Myers Squibb, Dava Oncology, Gilead, Illumina, Imedex, MedImmune, Omniprex, PeerView and Physician Education Resource; consultant/advisory board member for AstraZeneca, Biothera Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Micronoma, Novartis and Roche/Genentech. C.A.: consulting fees from Iovance. H.A.T.: research funding from GlaxoSmithKline; research funding and consulting honoraria from Bristol-Myers Squibb, Genentech, Merck and Novartis; consulting for Boxer, Eisai, Iovance, Karyopharm and Pfizer. All other authors report no conflicts of interest.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tawbi</surname>
                      <given-names>HA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2022</year>
                  <volume>386</volume>
                  <fpage>24</fpage>
                  <lpage>34</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2109970</pub-id>
                  <?supplied-pmid 34986285?>
                  <pub-id pub-id-type="pmid">34986285</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tetzlaff</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pathologic assessment of resection specimens after neoadjuvant therapy for metastatic melanoma</article-title>
                  <source>Ann. Oncol.</source>
                  <year>2018</year>
                  <volume>29</volume>
                  <fpage>1861</fpage>
                  <lpage>1868</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdy226</pub-id>
                  <pub-id pub-id-type="pmid">29945191</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gershenwald</surname>
                      <given-names>JE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Melanoma staging: evidence-based changes in the American Joint Committee on Cancer: eighth edition cancer staging manual</article-title>
                  <source>CA Cancer J. Clin.</source>
                  <year>2017</year>
                  <volume>67</volume>
                  <fpage>472</fpage>
                  <lpage>492</lpage>
                  <pub-id pub-id-type="doi">10.3322/caac.21409</pub-id>
                  <pub-id pub-id-type="pmid">29028110</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Long</surname>
                      <given-names>GV</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2017</year>
                  <volume>377</volume>
                  <fpage>1813</fpage>
                  <lpage>1823</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1708539</pub-id>
                  <pub-id pub-id-type="pmid">28891408</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eggermont</surname>
                      <given-names>AMMM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Adjuvant pembrolizumab versus placebo in resected stage III melanoma</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2018</year>
                  <volume>378</volume>
                  <fpage>1789</fpage>
                  <lpage>1801</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1802357</pub-id>
                  <?supplied-pmid 29658430?>
                  <pub-id pub-id-type="pmid">29658430</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weber</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Five-year outcomes with adjuvant nivolumab versus ipilimumab in resected stage IIIB-C or IV melanoma (CheckMate 238)</article-title>
                  <source>Pig. Cell Mel. Res.</source>
                  <year>2022</year>
                  <volume>35</volume>
                  <fpage>97</fpage>
                  <lpage>184</lpage>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <mixed-citation publication-type="other">Long, G. V. et al. Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma (CheckMate 915). <italic>Cancer Res.</italic>10.1158/1538-7445.AM2021-CT004 (2021).</mixed-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amaria</surname>
                      <given-names>RN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2019</year>
                  <volume>20</volume>
                  <fpage>e378</fpage>
                  <lpage>e389</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(19)30332-8</pub-id>
                  <?supplied-pmid 31267972?>
                  <pub-id pub-id-type="pmid">31267972</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Menzies</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</article-title>
                  <source>Nat. Med.</source>
                  <year>2021</year>
                  <volume>27</volume>
                  <fpage>301</fpage>
                  <lpage>309</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41591-020-01188-3</pub-id>
                  <?supplied-pmid 33558722?>
                  <pub-id pub-id-type="pmid">33558722</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Akkooi</surname>
                      <given-names>ACJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium</article-title>
                  <source>Ann. Surg. Oncol.</source>
                  <year>2022</year>
                  <volume>29</volume>
                  <fpage>3694</fpage>
                  <lpage>3708</lpage>
                  <pub-id pub-id-type="doi">10.1245/s10434-021-11236-y</pub-id>
                  <?supplied-pmid 35089452?>
                  <pub-id pub-id-type="pmid">35089452</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cortazar</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis</article-title>
                  <source>Lancet</source>
                  <year>2014</year>
                  <volume>384</volume>
                  <fpage>164</fpage>
                  <lpage>172</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(13)62422-8</pub-id>
                  <?supplied-pmid 24529560?>
                  <pub-id pub-id-type="pmid">24529560</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petrelli</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis</article-title>
                  <source>Eur. Urol.</source>
                  <year>2014</year>
                  <volume>65</volume>
                  <fpage>350</fpage>
                  <lpage>357</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.eururo.2013.06.049</pub-id>
                  <?supplied-pmid 23849998?>
                  <pub-id pub-id-type="pmid">23849998</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kasi</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Total neoadjuvant chemotherapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis</article-title>
                  <source>JAMA Netw. Open.</source>
                  <year>2020</year>
                  <volume>3</volume>
                  <fpage>e2030097</fpage>
                  <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.30097</pub-id>
                  <?supplied-pmid 33326026?>
                  <pub-id pub-id-type="pmid">33326026</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease</article-title>
                  <source>Cancer Disc.</source>
                  <year>2016</year>
                  <volume>6</volume>
                  <fpage>1382</fpage>
                  <lpage>1399</lpage>
                  <pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0577</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blank</surname>
                      <given-names>CU</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</article-title>
                  <source>Nat. Med.</source>
                  <year>2018</year>
                  <volume>24</volume>
                  <fpage>1655</fpage>
                  <lpage>1661</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41591-018-0198-0</pub-id>
                  <?supplied-pmid 30297911?>
                  <pub-id pub-id-type="pmid">30297911</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amaria</surname>
                      <given-names>RN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma</article-title>
                  <source>Nat. Med.</source>
                  <year>2018</year>
                  <volume>24</volume>
                  <fpage>1649</fpage>
                  <lpage>1654</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41591-018-0197-1</pub-id>
                  <?supplied-pmid 30297909?>
                  <pub-id pub-id-type="pmid">30297909</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rozeman</surname>
                      <given-names>EA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicenter, phase 2, randomized, controlled trial</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2019</year>
                  <volume>20</volume>
                  <fpage>948</fpage>
                  <lpage>960</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(19)30151-2</pub-id>
                  <?supplied-pmid 31160251?>
                  <pub-id pub-id-type="pmid">31160251</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Woo</surname>
                      <given-names>S-R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Immune inhibitory molecules LAG-3 and PD01 synergistically regulate T cell function to promote tumoral immune escape</article-title>
                  <source>Cancer Res.</source>
                  <year>2012</year>
                  <volume>72</volume>
                  <fpage>917</fpage>
                  <lpage>927</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1620</pub-id>
                  <?supplied-pmid 22186141?>
                  <pub-id pub-id-type="pmid">22186141</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anderson</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Joller</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Kuchroo</surname>
                      <given-names>VK</given-names>
                    </name>
                  </person-group>
                  <article-title>Lag-, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation</article-title>
                  <source>Immunity.</source>
                  <year>2016</year>
                  <volume>44</volume>
                  <fpage>989</fpage>
                  <lpage>1004</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.001</pub-id>
                  <?supplied-pmid 27192565?>
                  <pub-id pub-id-type="pmid">27192565</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ascierto</surname>
                      <given-names>PA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations</article-title>
                  <source>Ann. Oncol.</source>
                  <year>2017</year>
                  <volume>28</volume>
                  <fpage>V611</fpage>
                  <lpage>612</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdx440.011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huang</surname>
                      <given-names>AC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma</article-title>
                  <source>Nat. Med.</source>
                  <year>2019</year>
                  <volume>25</volume>
                  <fpage>454</fpage>
                  <lpage>461</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41591-019-0357-y</pub-id>
                  <?supplied-pmid 30804515?>
                  <pub-id pub-id-type="pmid">30804515</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amaria</surname>
                      <given-names>RN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2018</year>
                  <volume>19</volume>
                  <fpage>181</fpage>
                  <lpage>193</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30015-9</pub-id>
                  <?supplied-pmid 29361468?>
                  <pub-id pub-id-type="pmid">29361468</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Long</surname>
                      <given-names>GV</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2019</year>
                  <volume>20</volume>
                  <fpage>961</fpage>
                  <lpage>971</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(19)30331-6</pub-id>
                  <?supplied-pmid 31171444?>
                  <pub-id pub-id-type="pmid">31171444</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Forde</surname>
                      <given-names>PM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant PD-1 blockade in resectable lung cancer</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2018</year>
                  <volume>378</volume>
                  <fpage>1976</fpage>
                  <lpage>1986</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1716078</pub-id>
                  <?supplied-pmid 29658848?>
                  <pub-id pub-id-type="pmid">29658848</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Topalian</surname>
                      <given-names>SL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2020</year>
                  <volume>38</volume>
                  <fpage>2476</fpage>
                  <lpage>2487</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.20.00201</pub-id>
                  <?supplied-pmid 32324435?>
                  <pub-id pub-id-type="pmid">32324435</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vos</surname>
                      <given-names>JL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant immunotherapy with nivolumab and ipilimumab induces a major pathologic response in patients with head and neck squamous cell carcinoma</article-title>
                  <source>Nat. Commun.</source>
                  <year>2021</year>
                  <volume>12</volume>
                  <fpage>7348</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41467-021-26472-9</pub-id>
                  <?supplied-pmid 34937871?>
                  <pub-id pub-id-type="pmid">34937871</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Riaz</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Tumor and microenvironment evolution during immunotherapy with nivolumab</article-title>
                  <source>Cell</source>
                  <year>2017</year>
                  <volume>171</volume>
                  <fpage>934</fpage>
                  <lpage>949</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cell.2017.09.028</pub-id>
                  <?supplied-pmid 29033130?>
                  <pub-id pub-id-type="pmid">29033130</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rozeman</surname>
                      <given-names>EA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Survival and biomarker analyses from OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma</article-title>
                  <source>Nat. Med.</source>
                  <year>2021</year>
                  <volume>27</volume>
                  <fpage>256</fpage>
                  <lpage>263</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41591-020-01211-7</pub-id>
                  <?supplied-pmid 33558721?>
                  <pub-id pub-id-type="pmid">33558721</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jordan</surname>
                      <given-names>KR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients</article-title>
                  <source>Cancer Immunol. Immunother.</source>
                  <year>2013</year>
                  <volume>62</volume>
                  <fpage>1711</fpage>
                  <lpage>1722</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00262-013-1475-x</pub-id>
                  <?supplied-pmid 24072401?>
                  <pub-id pub-id-type="pmid">24072401</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Llao-Cid</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia</article-title>
                  <source>Leukemia</source>
                  <year>2021</year>
                  <volume>35</volume>
                  <fpage>3152</fpage>
                  <lpage>3162</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41375-021-01198-1</pub-id>
                  <pub-id pub-id-type="pmid">33731848</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Helmink</surname>
                      <given-names>BA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>B cells and tertiary lymphoid structures promote immunotherapy response</article-title>
                  <source>Nature</source>
                  <year>2020</year>
                  <volume>277</volume>
                  <fpage>549</fpage>
                  <lpage>555</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41586-019-1922-8</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eisenhauer</surname>
                      <given-names>EA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>
                  <source>Eur. J. Cancer.</source>
                  <year>2009</year>
                  <volume>45</volume>
                  <fpage>228</fpage>
                  <lpage>247</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
                  <pub-id pub-id-type="pmid">19097774</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <mixed-citation publication-type="other">U.S. Department of Health and Human Services,National Institutes of Health &amp; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4.03. <ext-link ext-link-type="uri" xlink:href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf</ext-link> (2010).</mixed-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nowicka</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets</article-title>
                  <source>F1000Res.</source>
                  <year>2017</year>
                  <volume>6</volume>
                  <fpage>748</fpage>
                  <pub-id pub-id-type="doi">10.12688/f1000research.11622.1</pub-id>
                  <?supplied-pmid 28663787?>
                  <pub-id pub-id-type="pmid">28663787</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
